T1	CHEM 44 55	Erdafitinib
T2	CHEM 57 61	ERDA
T3	CHEM 89 99	cetrelimab
T4	CHEM 101 104	CET
T5	PROC 111 135	tratamiento neoadyuvante
T6	PROC 149 156	cirugía
#1	AnnotatorNotes T6	C0543467; Operative Surgical Procedures; Therapeutic or Preventive Procedure
T7	LIVB 161 168	sujetos
#2	AnnotatorNotes T7	C0681850; Study Subject; Group
T8	DISO 173 206	cáncer de vejiga músculo-invasivo
T9	DISO 213 220	tumores
#3	AnnotatorNotes T9	C0027651; Neoplasms; Neoplastic Process | C0038999; Swelling; Finding
T10	Neg_cue 258 260	no
T11	PROC 288 299	tratamiento
#4	AnnotatorNotes T11	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T12	Negated 288 299	tratamiento
T13	CHEM 304 314	cisplatino
#5	AnnotatorNotes T13	C0008838; cisplatin; Inorganic Chemical · Pharmacologic Substance
T14	Negated 304 314	cisplatino
T15	PROC 335 410	Estudio de fase 2, intervencionista, abierto, multicéntrico y multinacional
T16	PROC 417 451	evaluar la eficacia y la seguridad
T17	CHEM 455 466	erdafitinib
T18	CHEM 468 472	ERDA
T19	PROC 477 488	monoterapia
#6	AnnotatorNotes T19	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T20	CHEM 510 520	cetrelimab
T21	CHEM 522 525	CET
T22	PROC 532 556	tratamiento neoadyuvante
T23	LIVB 560 569	pacientes
#7	AnnotatorNotes T23	C0030705; Patients; Patient or Disabled Group
T24	DISO 626 631	tumor
#8	AnnotatorNotes T24	C0027651; Neoplasms; Neoplastic Process | C0038999; Swelling; Finding
T25	Neg_cue 672 674	no
T26	PROC 693 704	tratamiento
#9	AnnotatorNotes T26	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T27	Negated 693 704	tratamiento
T28	CHEM 709 719	cisplatino
#10	AnnotatorNotes T28	C0008838; cisplatin; Inorganic Chemical · Pharmacologic Substance
T29	Negated 709 719	cisplatino
T30	PROC 884 920	Consentimiento informado por escrito
T31	LIVB 948 956	paciente
#11	AnnotatorNotes T31	C0030705; Patients; Patient or Disabled Group
T32	PROC 998 1012	procedimientos
T33	PROC 1062 1073	Diagnóstico
#12	AnnotatorNotes T33	C0011900; Diagnosis; Diagnostic Procedure
T34	DISO 1117 1121	MIBC
T35	PROC 1166 1182	histológicamente
T36	PROC 1226 1266;1317 1328;1331 1337	resección transuretral del tumor vesical diagnóstica máxima
T37	PROC 1268 1273	TURBT
T38	Neg_cue 1349 1351	no
T39	Duration 1352 1366	más de 3 meses
T40	Negated 1352 1366	más de 3 meses
T41	PROC 1388 1407	visita de selección
T42	PROC 1413 1423	Histología
#13	AnnotatorNotes T42	C0344441; Histology Procedure; Laboratory Procedure
T43	DISO 1454 1473	carcinoma urotelial
#14	AnnotatorNotes T43	C0007138; Carcinoma, Transitional Cell; Neoplastic Process
T44	DISO 1475 1477	UC
T45	Age 1551 1560	≥ 18 años
T46	PROC 1566 1582	Estado funcional
T47	LIVB 1644 1652	paciente
#15	AnnotatorNotes T47	C0030705; Patients; Patient or Disabled Group
T48	Neg_cue 1653 1660	rechaza
T49	Neg_cue 1663 1665	no
T50	Neg_cue 1680 1682	no
T51	Negated 1683 1687	apto
T52	Negated 1695 1715	quimioterapia a base
T53	CHEM 1695 1708	quimioterapia
#16	AnnotatorNotes T53	C0013216; Pharmacotherapy; Therapeutic or Preventive Procedure | C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T54	CHEM 1719 1729	cisplatino
#17	AnnotatorNotes T54	C0008838; cisplatin; Inorganic Chemical · Pharmacologic Substance
T55	Negated 1719 1729	cisplatino
T56	DISO 1764 1783	alteración del FGFR
T57	PROC 1790 1820	análisis de la biopsia tumoral
T58	PHYS 1825 1841	Función orgánica
T59	Neg_cue 1855 1866	Ausencia de
T60	DISO 1873 1892	neoplasias malignas
#18	AnnotatorNotes T60	C0006826; Malignant Neoplasms; Neoplastic Process | C1306459; Primary malignant neoplasm; Neoplastic Process
T61	Neg_cue 1913 1919	evitar
T62	PHYS 1923 1931	embarazo
#19	AnnotatorNotes T62	C0032961; Pregnancy; Organism Function
T63	Negated 1923 1931	embarazo
T64	PHYS 1934 1943	engendrar
T65	LIVB 1944 1949	hijos
T66	DISO 2001 2006	tumor
#20	AnnotatorNotes T66	C0027651; Neoplasms; Neoplastic Process | C0038999; Swelling; Finding
T67	DISO 2015 2043	cáncer de vejiga metastásico
T68	DISO 2049 2054	Tumor
#21	AnnotatorNotes T68	C0027651; Neoplasms; Neoplastic Process | C0038999; Swelling; Finding
T69	ANAT 2080 2094	neuroendocrino
#22	AnnotatorNotes T69	C0027912; Neurosecretory Systems; Body System
T70	ANAT 2097 2109	microcelular
T71	LIVB 2115 2124	Pacientes
#23	AnnotatorNotes T71	C0030705; Patients; Patient or Disabled Group
T72	Neg_cue 2125 2127	no
T73	PROC 2155 2166	cistectomía
#24	AnnotatorNotes T73	C0010651; Cystectomy; Therapeutic or Preventive Procedure
T74	Negated 2155 2166	cistectomía
T75	Neg_cue 2173 2181	rechacen
T76	PROC 2187 2199	intervención
#25	AnnotatorNotes T76	C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T77	Negated 2187 2199	intervención
T78	PROC 2204 2225	Tratamiento sistémico
T79	CHEM 2245 2249	FGFR
T80	CHEM 2252 2264	antiPD1/PDL1
T81	Neg_cue 2270 2272	No
T82	PROC 2306 2327	tratamiento sistémico
T83	Negated 2306 2327	tratamiento sistémico
T84	PROC 2329 2341	radioterapia
#26	AnnotatorNotes T84	C0041626; Ultraviolet Therapy; Therapeutic or Preventive Procedure | C1522449; Therapeutic radiology procedure; Therapeutic or Preventive Procedure
T85	Negated 2329 2341	radioterapia
T86	PROC 2344 2351	cirugía
#27	AnnotatorNotes T86	C0543467; Operative Surgical Procedures; Therapeutic or Preventive Procedure
T87	Negated 2344 2351	cirugía
T88	DISO 2360 2376	cáncer de vejiga
#28	AnnotatorNotes T88	C0005684; Malignant neoplasm of urinary bladder; Neoplastic Process
T89	DISO 230 250	alteraciones del gen
T90	DISO 582 620	cáncer de vejiga con invasión muscular
T91	DISO 640 660	alteraciones del gen
T92	DISO 816 853	Cáncer de vejiga con invasión muscula
T93	DISO 742 791	Cáncer de vejiga que se propaga al musculo grueso
T94	DISO 1123 1153	muscle-invasive bladder cancer
T95	DISO 1077 1115	cáncer de vejiga con invasión muscular
T96	PROC 1275 1316	transurethral resection of bladder tumor)
T97	DISO 1479 1499	urothelial carcinoma
T98	Route 2216 2225	sistémico
T99	Route 2318 2327	sistémico
T100	Negated 1934 1949	engendrar hijos
T101	Negated 1867 1892	otras neoplasias malignas
T102	Quantifier_or_Qualifier 63 67	solo
T103	Observation 190 206	músculo-invasivo
T104	Observation 1025 1056	acepta participar en el estudio
T105	Observation 1192 1206	T2-4a N0/N1 M0
T106	Quantifier_or_Qualifier 1424 1428	pura
T107	Quantifier_or_Qualifier 1431 1443	predominante
T108	Quantifier_or_Qualifier 1448 1450	%)
T109	CONC 1587 1621	Eastern Cooperative Oncology Group
T110	CONC 1623 1627	ECOG
T111	Result_or_Value 1632 1635	0-1
T112	Observation 1683 1687	apto
T113	Observation 1825 1850	Función orgánica adecuada
T114	Quantifier_or_Qualifier 1867 1872	otras
T115	CONC 1980 1997	Evidencia clínica
T116	Observation 2007 2012	N2-N3
T117	Observation 2069 2079	componente
T118	Patient 161 168	sujetos
T119	Patient 560 569	pacientes
T120	Patient 948 956	paciente
T121	Patient 1644 1652	paciente
T122	Family_member 1944 1949	hijos
T123	Patient 2115 2124	Pacientes
T124	History_of 2204 2225	Tratamiento sistémico
T125	History_of 2245 2249	FGFR
T126	History_of 2252 2265	antiPD1/PDL1.
T127	History_of 2306 2327	tratamiento sistémico
T128	History_of 2329 2341	radioterapia
T129	History_of 2344 2351	cirugía
